Plastic and Cosmetic Surgery
Also known as: Cosmetic surgery
Methodology & AI Transparency ⓘ
Plastic and Cosmetic Surgery Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Surgeons can reshape the appearance of body parts through cosmetic surgery.
- 2 Real-world patient consensus: Diagnostic registry L23.0: Plastic and Cosmetic Surgery is managed within Skin & Dermatology (aka Cosmetic surgery).
- 3 Typical cash cost range: Workup highlights for Plastic and Cosmetic Surgery (L23.0): or targeted biologics [Plastic and Cosmetic Surgery L23.0].
- 4 Top reported side effects / signs: Key Skin & Dermatology biomarkers for Plastic and Cosmetic Surgery (L23.0): Fasting Lipids & in Plastic and Cosmetic Surgery (L23.0: ALT (if systemic) & 25-Hydroxy Vitamin D in Plastic and Cosmetic Surgery (L23.0: & hs-CRP) (25(OH)D 40–65 ng/mL (L23.0)).
Ask our AI Specialists anything about Plastic and Cosmetic Surgery
What Is Plastic and Cosmetic Surgery?
Surgeons can reshape the appearance of body parts through cosmetic surgery. Some of the most common body parts people want to improve through surgery include: Breasts: Increase or reduce the size of breasts or reshape sagging breasts Ears: Reduce the size of large ears or set protruding ears back closer to the head Eyes: Correct drooping upper eyelids or remove puffy bags below the eyes Face: Remove facial wrinkles, creases or acne scars Hair: Fill in balding areas with one's own hair Nose: Change the shape of the nose Tummy: Flatten the abdomen
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Plastic and Cosmetic Surgery (L23.0, Skin & Dermatology) reflects cutaneous immune skewing in Plastic and Cosmetic Surgery (L23.0: (Th2/IL-4/IL-13 in atopic). Cross-referenced with NIH MeSH (Plastic Surgery Procedures), longitudinal control is benchmarked via Fasting Lipids & in Plastic and Cosmetic Surgery (L23.0: ALT (if systemic).
Common Symptoms & Clinical Signs
- • Breasts: Increase or reduce the size of breasts or reshape sagging breasts
- • Ears: Reduce the size of large ears or set protruding ears back closer to the head
- • Presentation of Plastic and Cosmetic Surgery (L23.0): compromised epidermal barrier in Plastic and Cosmetic Surgery (L23.0: with dryness, fissuring,)
- • Secondary Plastic and Cosmetic Surgery clinical sign: post-inflammatory hyperpigmentation, facial in Plastic and Cosmetic Surgery (L23.0: flushing, or pitted)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Plastic and Cosmetic Surgery Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L23.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Fasting Lipids & in Plastic and Cosmetic Surgery (L23.0: ALT (if systemic) | Within baseline reference limits (L23.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Plastic and Cosmetic Surgery (L23.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (L23.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Plastic and Cosmetic Surgery (L23.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L23.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Plastic and Cosmetic Surgery
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Botox Cosmetic (Onabotulinumtoxina) Botox Cosmetic • RxCUI RXN-B00233919 | Acetylcholine Release Inhibitor | 83% | $3.1300 | $ 233.86 /mo |
| Lacura Blemish Dots Conceal and Treat (Salicylic Acid 0.5%) Lacura Blemish Dots Conceal and Treat • RxCUI 1994404-B56136181 | FDA Prescription Therapeutic Agent | 79% | $4.9868 | $ 367.55 /mo |
| 4% Lidocaine Patch Relieved Pro Wrap • RxCUI 1737778 | Amide Local Anesthetic | 93% | $0.8000 | $ 40.90 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Plastic and Cosmetic Surgery)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Plastic-related endocrine disrupting chemicals significantly related to the: What a 83,641-Participant Study Found Increased serum, urinary, or dietary concentration of MBzP and MEHP in women is significantly associated with endometriosis risk. Environmental research • 2024-07-01 • Meta-Analysis | N = 83,641 | 94/100 | PMID 38640992 ↗ |
| New Insights on Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome:: What a 272-Participant Study Found Despite MATTERHORN not meeting its primary endpoint, a numerically higher TI rate was achieved with roxadustat treatment compared with placebo. American journal of hematology • 2024-09-15 • Phase III Randomized Trial | N = 272 | 93/100 | PMID 38884137 ↗ |
| Can This Approach Help? Inside the Latest Research on Phase I Clinical Trial of SyB C-1101 in Patients With Myelodysplastic Syndrome - This is an extension study to investigate long term safety and efficacy of SyB C-1101 when orally administered every 3 weeks, twice daily for 14 consecutive days to the patients who have completed 6 cycles in the study 2012002 whose purpose ClinicalTrials.gov Registry (NIH NLM) • 2014-12-01 • Completed Human Clinical Trial (NCT) | N = 1 | 89/100 | PMID NCT02002936 ↗ |
| Can This Approach Help? Inside the Latest Research on Modulation of the clonal burden in patients with lower-risk myelodysplastic Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA. Leukemia • 2026-02-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41526614 ↗ |
| Can This Approach Help? Inside the Latest Research on Imetelstat improves patient-reported outcomes and quality of life in lower-risk 37%, 41%, and 44%, respectively; P<0.001, P=0.004, and P=0.002) and QOL across different measures of response (43-53% vs. Haematologica • 2026-07-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41568521 ↗ |
Plastic and Cosmetic Surgery Patient Community & “People Like Me” Threads
Filter Plastic and Cosmetic Surgery community threads and patient logs by age, biological sex, dosage, and treatment duration.